AB SCIENCE SA (AB.PA)
FR0010557264 - Common Stock
Taking everything into account, AB scores 1 out of 10 in our fundamental rating. AB was compared to 51 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AB have multiple concerns. AB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AB had negative earnings in the past year.
AB had a negative operating cash flow in the past year.
AB had negative earnings in each of the past 5 years.
AB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -47.00%, AB is doing worse than 82.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-57.37%
ROA(5y)-69.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 60.52%, AB is not doing good in the industry: 65.96% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of AB has declined.
The Profit Margin and Operating Margin are not available for AB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-6.66%
2. Health
2.1 Basic Checks
AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AB has more shares outstanding
Compared to 5 years ago, AB has more shares outstanding
Compared to 1 year ago, AB has an improved debt to assets ratio.
2.2 Solvency
AB has an Altman-Z score of -16.24. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.24, AB is doing worse than 95.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.24 |
ROIC/WACCN/A
WACC6.36%
2.3 Liquidity
AB has a Current Ratio of 1.04. This is a normal value and indicates that AB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.04, AB is not doing good in the industry: 74.47% of the companies in the same industry are doing better.
A Quick Ratio of 1.02 indicates that AB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.02, AB is in the better half of the industry, outperforming 61.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
AB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.71%, which is quite good.
AB shows a small growth in Revenue. In the last year, the Revenue has grown by 1.25%.
The Revenue for AB have been decreasing by -10.63% on average. This is quite bad
EPS 1Y (TTM)13.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.85%
Revenue 1Y (TTM)1.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y-10.63%
Sales Q2Q%58.66%
3.2 Future
The Earnings Per Share is expected to grow by 14.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.50% on average over the next years. This is quite good.
EPS Next Y38.24%
EPS Next 2Y18.59%
EPS Next 3Y14.36%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y17.78%
Revenue Next 3Y14.5%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AB's earnings are expected to grow with 14.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.59%
EPS Next 3Y14.36%
5. Dividend
5.1 Amount
No dividends for AB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AB SCIENCE SA
EPA:AB (10/22/2024, 5:01:55 PM)
0.95
+0.01 (+1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)13.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y